CRISPR Therapeutics’ (CRSP) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reiterated their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research report report published on Friday morning,Benzinga reports. JMP Securities currently has a $86.00 price target on the stock.

Other research analysts have also issued research reports about the stock. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. Barclays reduced their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a research note on Friday, May 9th. Wall Street Zen raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, May 16th. Chardan Capital reissued a “buy” rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $71.75.

CRISPR Therapeutics Trading Up 1.7%

Shares of NASDAQ CRSP opened at $47.49 on Friday. The firm has a market capitalization of $4.10 billion, a PE ratio of -10.51 and a beta of 1.75. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $63.68. The firm’s 50-day moving average is $39.48 and its 200-day moving average is $40.55.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The company’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.43) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider now directly owns 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Magnetar Financial LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $359,000. Baker BROS. Advisors LP increased its holdings in CRISPR Therapeutics by 55.1% during the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock worth $51,483,000 after buying an additional 464,936 shares during the last quarter. Vanguard Group Inc. increased its holdings in CRISPR Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock worth $68,329,000 after buying an additional 10,579 shares during the last quarter. Green Alpha Advisors LLC increased its holdings in CRISPR Therapeutics by 132.9% during the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company’s stock worth $1,952,000 after buying an additional 32,732 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in CRISPR Therapeutics during the fourth quarter worth $3,231,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.